Tenderwize
Retour à la recherche

Non-exclusive discount agreement for Ebastin (ATC R06AX22)

AOK Niedersachsen. Die Gesundheitskasse.·Hannover, Germany·Deadline May 27, 2027 · 279 days left·Open·Supplies·Framework
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Ebastin (ATC-Code: R06AX22).

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

20 / 100

Facteurs de risque

The buyer may replace open-house contracts with exclusive contracts at any time. Open-house contracts end automatically...

There is no commitment to purchase any minimum quantity. The agreement only provides a discount framework.

No procurement documents available

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jul 2027
  • Supply of pharmaceutical products with active ingredient Ebastin (ATC R06AX22) under a non-exclusive discount agreement with AOK Niedersachsen.
Afficher le résumé complet

Non-exclusive discount agreement (open-house model) for Ebastin (ATC R06AX22) pharmaceuticals, open to all eligible pharmaceutical companies without selection. Operates as a bridge until exclusive contracts are awarded. Paper-based submission, uniform conditions, no negotiation.

Risques

The buyer may replace open-house contracts with exclusive contracts at any time. Open-house contracts end automatically...

There is no commitment to purchase any minimum quantity. The agreement only provides a discount framework.

No procurement documents available

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) as defined in § 4 Abs. 18 AMG for the offered medicinal products.
  • Place of performance: Lower Saxony, Germany.

Administrative

  • Paper-based submission only – electronic submission not allowed.

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

Price – no weight given.

Acheteur

Localisation

Hannover, DEU

Identifiant

AOK- Niedersachsen. Die Gesundheitskasse

Activité

Health

Lots (1)

LOT-0000

Non-exclusive discount agreement for Ebastin (ATC R06AX22)

Open-house model allowing any eligible pharmaceutical company to enter into a non-exclusive discount agreement for Ebastin products. Maximum 24-month duration, ending by 31 July 2027. First start date 1 August 2025. Early replacement by exclusive contracts possible.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE929, Germany

Durée

Jul 2025 - Jul 2027

Catégorie

Pharmaceutical products

Critères d'attribution

Price

Date limite

Expired Jun 27, 2025

Détails de la procédure

Date de publication
10 Jun 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
373012-2025

Appels d'offres similaires